News

Shares of Danaher Co. (NYSE:DHR - Get Rating) have earned a consensus rating of "Moderate Buy" from the fourteen analysts that are covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and ten have issued a buy recommendation on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $310.17.

Several brokerages have issued reports on DHR. Barclays cut their target price on Danaher from $285.00 to $277.00 and set an "overweight" rating for the company in a research note on Tuesday, November 29th. StockNews.com lowered Danaher from a "strong-buy" rating to a "buy" rating in a research note on Thursday. Robert W. Baird dropped their price objective on Danaher from $325.00 to $315.00 and set an "outperform" rating for the company in a research note on Friday, October 21st. JPMorgan Chase & Co. decreased their target price on Danaher from $350.00 to $315.00 and set an "overweight" rating for the company in a report on Friday, October 21st. Finally, Credit Suisse Group decreased their target price on Danaher to $315.00 in a report on Thursday, October 27th.

Insider Transactions at Danaher

In other news, SVP Georgeann Couchara sold 1,884 shares of the firm's stock in a transaction dated Tuesday, November 15th. The stock was sold at an average price of $271.61, for a total value of $511,713.24. Following the transaction, the senior vice president now owns 2,588 shares of the company's stock, valued at $702,926.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, SVP Georgeann Couchara sold 1,884 shares of Danaher stock in a transaction that occurred on Tuesday, November 15th. The stock was sold at an average price of $271.61, for a total transaction of $511,713.24. Following the sale, the senior vice president now owns 2,588 shares of the company's stock, valued at approximately $702,926.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Alan G. Spoon sold 500 shares of Danaher stock in a transaction that occurred on Tuesday, October 25th. The shares were sold at an average price of $252.93, for a total value of $126,465.00. Following the sale, the director now directly owns 107,135 shares in the company, valued at approximately $27,097,655.55. The disclosure for this sale can be found here. Insiders have sold 39,038 shares of company stock valued at $10,550,749 over the last quarter. 11.20% of the stock is currently owned by company insiders.

Institutional Trading of Danaher

Large investors have recently added to or reduced their stakes in the company. Advisor OS LLC boosted its holdings in Danaher by 0.6% during the 2nd quarter. Advisor OS LLC now owns 6,253 shares of the conglomerate's stock valued at $1,585,000 after acquiring an additional 37 shares during the period. American National Bank raised its position in Danaher by 31.9% during the 3rd quarter. American National Bank now owns 157 shares of the conglomerate's stock valued at $41,000 after purchasing an additional 38 shares in the last quarter. Stonebridge Capital Advisors LLC raised its position in shares of Danaher by 9.7% in the 3rd quarter. Stonebridge Capital Advisors LLC now owns 428 shares of the conglomerate's stock worth $111,000 after acquiring an additional 38 shares in the last quarter. Strengthening Families & Communities LLC raised its position in shares of Danaher by 3.2% in the 2nd quarter. Strengthening Families & Communities LLC now owns 1,248 shares of the conglomerate's stock worth $364,000 after acquiring an additional 39 shares in the last quarter. Finally, Journey Advisory Group LLC raised its position in shares of Danaher by 2.5% in the 2nd quarter. Journey Advisory Group LLC now owns 1,648 shares of the conglomerate's stock worth $475,000 after acquiring an additional 40 shares in the last quarter. Institutional investors own 77.27% of the company's stock.

Danaher Trading Down 0.9 %

NYSE DHR opened at $269.34 on Friday. Danaher has a one year low of $233.71 and a one year high of $331.23. The business's fifty day moving average is $260.68 and its 200-day moving average is $266.38. The stock has a market capitalization of $196.07 billion, a price-to-earnings ratio of 29.76, a PEG ratio of 2.12 and a beta of 0.83. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.78 and a quick ratio of 1.38.

Danaher (NYSE:DHR - Get Rating) last announced its quarterly earnings results on Thursday, October 20th. The conglomerate reported $2.56 earnings per share for the quarter, beating the consensus estimate of $2.24 by $0.32. Danaher had a return on equity of 18.33% and a net margin of 21.65%. The firm had revenue of $7.66 billion for the quarter, compared to analysts' expectations of $7.17 billion. During the same period in the prior year, the business posted $2.39 earnings per share. The company's revenue was up 6.0% on a year-over-year basis. Equities research analysts predict that Danaher will post 10.53 EPS for the current year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 27th. Shareholders of record on Friday, December 30th will be given a $0.25 dividend. The ex-dividend date of this dividend is Thursday, December 29th. This represents a $1.00 annualized dividend and a yield of 0.37%. Danaher's payout ratio is 11.05%.

Danaher Company Profile

(Get Rating)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider Danaher, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.

While Danaher currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.